

Sareum Holdings PLC

("Sareum" or the "Company")

Director's Dealing

Cambridge, UK, 27 March 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that Dr Stephen Parker, Executive Chairman, purchased 84,033 ordinary shares of 1.25 pence each in the capital of the Company ("**Ordinary Shares**") at an average price of 11.9 pence per share on 26 March 2025.

In addition, persons connected with Dr Parker are interested in a further 25,680 Ordinary Shares in the Company, over which Ordinary Shares Dr Parker has voting rights discretion.

Therefore, following the transaction, Dr Parker has direct and indirect interests in an aggregate 405,045 Ordinary Shares in the Company, representing approximately 0.30 per cent. of the Company's currently issued share capital.

The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further details.

PDMR Notification Form:

1	Details of the person discharging managerial responsibilities/person closely associated			
a)	Name	Stephen Parker		
2	Reason for the notification			
a)	Position/status	Executive Chairman		
b)	Initial notification/amendment	Initial notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	Sareum Holdings plc		
b)	LEI	213800PKERN2DY8FFM72		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1.25 pence each in the share capital of Sareum Holdings plc		
	Identification code	GB00B02RFS12		
b)	Nature of the transaction	Purchase of shares		
c)	Price(s) and volume(s)			
		Price(s)	Volume(s)	
		£0.119	84,033	
d)	Aggregated information			
	- Aggregated volume	84,033 Ordinary Shares		
	- Weighted Average Price	11.9 pence per Ordinary Share		
e)	Date of the transaction	26 March 2025		
f)	Place of the transaction	London Stock Exchange (AIM)		

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

- ENDS-

For further information, please contact:

Sareum Holdings plc
Stephen Parker, Executive Chairman

01223 497700
ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman

020 7409 3494

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering

020 3179 5300

Hybridan LLP (Joint Broker)
Claire Noyce

020 3764 2341

ICR Healthcare (Financial PR)
Jessica Hodgson / Davide Salvi

020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHMZGZFFVVVGKZM